Reduction of post injury neointima formation due to 17β-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182,780 in vitro

BMC Cardiovascular Disorders

Hartmut Hanke²  Thomas Schochat¹  Christina Lenz²  Gerald Finking¹ 

[1] Institute of Occupational, Social, and Environmental Medicine, University of Ulm, Ulm, Germany;Department of Cardiology, University of Ulm, Ulm, Germany

关键词: estrogen receptor;    ICI 182,780;    phytoestrogens;    17β-estradiol;    vascular injury;   

Others  :  1088624
DOI  :  10.1186/1471-2261-2-13

 received in 2002-05-28, accepted in 2002-08-06,  发布年份 2002

【 摘 要 】

Background

Animal and organ culture experiments have shown beneficial inhibitory estrogen effects on post injury neointima development. The purpose of this study was to investigate whether such estrogen effects are influenced by the estrogen receptor antagonist ICI 182,780. Different concentrations of 17β-estradiol and the phytoestrogens genistein and daidzein were tested.

Methods

F emale New Zealand White rabbits were benumbed. In situ vascular injury of the thoracic and abdominal aorta was performed by a 3F Fogarty catheter. Segments of 5 mm were randomised and held in culture for 21 days. Three test series were performed: 1) control group – 20 μM ICI – 30 μM ICI – 40 μM ICI. 2) control group – 20 μM ICI – 40 μM 17β-estradiol – 40 μM 17β-estradiol + 20 μM ICI. 3) control group – 20 μM ICI – 40 μM daidzein – 40 μM daidzein + 20 μM ICI – 20 μM genistein – 20 μM genistein + 20 μM ICI. After 21 days the neointima-media-ratio was evaluated.

Results

1) Treatment with ICI 182,780 did not reduce neointima formation significantly (p = 0.05). 2) 40 μM 17β-estradiol alone (p < 0.0001) and in combination with 20 μM ICI (p < 0.0001) reduced neointima formation significantly. 3) 20 μM genistein alone (p = 0.0083) and combined with 20 μM ICI (p = 0.0053) reduced neointima formation significantly. 40 μM daidzein did not have a significant (p = 0.0637) effect.

Conclusions

The estrogen receptor antagonist ICI 182,780 did not modulate the inhibitory estrogen effects on post injury neointima formation. These results do not support the idea that such effects are mediated by vascular estrogen receptors.

【 授权许可】

   
2002 Finking et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811.
• [2]Finking G, Gohar MH, Lenz C, Hanke H: Die Wirkungen von Ostrogen im kardiovaskularen System. Z Kardiol 2000, 89:442-453.
• [3]Finking G, Gohar MH, Lenz C, Hanke H: Cardiovascular oestrogen effects in women. J Obstet Gynaecol 2001, 21:340-349.
• [4]Sullivan JM, Vander-Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM: Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990, 150:2557-2562.
• [5]Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775.
• [6]Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama 1998, 280:605-613.
• [7]O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf RM: Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996, 28:1111-1118.
• [8]O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD: Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1-5.
• [9]Anonymous: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Jama 273:199-208.
• [10]Sack MN, Rader DJ, Cannon RO: Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
• [11]Vargas R, Wroblewska B, Rego A, Hatch J, Ramwell PW: Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993, 109:612-617.
• [12]Krasinski K, Spyridopoulos I, Asahara T, van-der-Zee R, Isner JM, Losordo DW: Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997, 95:1768-1772.
• [13]Chen SJ, Li H, Durand J, Oparil S, Chen YF: Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996, 93:577-584.
• [14]Oparil S, Chen SJ, Chen YF, Durand JN, Allen L, Thompson JA: Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. Cardiovasc Res 1999, 44:608-614.
• [15]Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT: Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992, 106:739-745.
• [16]Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P: Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro. Br J Pharmacol 1991, 104:1033-1037.
• [17]Gilligan DM, Quyyumi AA, Cannon RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551.
• [18]Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO: Acute vascular effects of estrogen in postmenopausal women. Circulation 1994, 90:786-791.
• [19]Finking G, Hess B, Hanke H: The value of phytoestrogens as a possible therapeutic option in postmenopausal women with coronary heart disease. J Obstet Gynaecol 1999, 19:455-459.
• [20]Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987, 262:5592-5595.
• [21]Bischof G, Illek B, Reenstra WW, Machen TE: Role for tyrosine kinases in carbachol-regulated Ca entry into colonic epithelial cells. Am J Physiol 1995, 268:C154-161.
• [22]Finking G, Lenz C, Wohlfrom M, Hanke H: In vitro Modell zur Untersuchung der Wirkung von ostrogenen auf die Neointimabildung nach Endothelverletzung an der Kaninchenaorta. Altex 2000, 17:11-14.
• [23]Finking G, Wohlfrom M, Lenz C, Wolkenhauer M, Eberle C, Brehme U, Bruck B, Hanke H: The effect of 17beta-estradiol, and the phytoestrogens genistein and daidzein on neointima development in endothelium-denuded female rabbit aortae–an in vitro study. Endothelium 2000, 7:99-107.
• [24]Finking G, Wohlfrom M, Lenz C, Wolkenhauer M, Eberle C, Hanke H: The phytoestrogens Genistein and Daidzein, and 17 beta-estradiol inhibit development of neointima in aortas from male and female rabbits in vitro after injury. Coron Artery Dis 1999, 10:607-615.
• [25]Finking G, Wolkenhauer M, Lenz C, Hanke H: Post-injury ex vivo model to investigate effects and toxicity of pharmacological treatment in rings of rabbit aortic vessels. Altex 2000, 17:67-74.
• [26]Lin AL, McGill HC, Shain SA: Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors. Circ Res 1982, 50:610-616.
• [27]Karas RH, Patterson BL, Mendelsohn ME: Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994, 89:1943-1950.
• [28]Venkov CD, Rankin AB, Vaughan DE: Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996, 94:727-733.
• [29]Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93:5925-5930.
• [30]Grohe C, Kahlert S, Lobbert K, Vetter H: Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. J Endocrinol 1998, 156:R1-7.
• [31]Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L: Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997, 416:107-112.
• [32]Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
• [33]Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
• [34]Barchiesi F, Jackson E-K, Gillespie D-G, Zacharia L-C, Fingerle J, Dubey R-K: Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 2002, 39:874-879.
• [35]Jonas JC, Plant TD, Gilon P, Detimary P, Nenquin M, Henquin JC: Multiple effects and stimulation of insulin secretion by the tyrosine kinase inhibitor genistein in normal mouse islets. Br J Pharmacol 1995, 114:872-880.
• [36]Negrescu EV, de-Quintana KL, Siess W: Platelet shape change induced by thrombin receptor activation. Rapid stimulation of tyrosine phosphorylation of novel protein substrates through an integrin- and Ca(2+)-independent mechanism. J Biol Chem 1995, 270:1057-1061.
• [37]Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan TR Jr, Lubahn DB, O'Donnell TF Jr, Korach KS, Mendelsohn ME: Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 1997, 3:545-548.
• [38]Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME: Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A 1999, 96:15133-15136.
• [39]Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ: Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999, 33:177-182.
• [40]Bakir S, Mori T, Durand J, Chen YF, Thompson JA, Oparil S: Estrogen-induced vasoprotection is estrogen receptor dependent: evidence from the balloon-injured rat carotid artery model. Circulation 2000, 101:2342-2344.
• [41]Karamsetty MR, Klinger JR, Hill NS: Phytoestrogens restore nitric oxide-mediated relaxation in isolated pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Ther 2001, 297:968-974.
• [42]Wade CB, Robinson S, Shapiro RA, Dorsa DM: Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 2001, 142:2336-2342.
• [43]Van-Den-Bemd GJ, Kuiper GG, Pols HA, Van-Leeuwen JP: Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 1999, 261:1-5.
• [44]Robertson JA, Zhang Y, Ing NH: ICI 182,780 acts as a partial agonist and antagonist of estradiol effects in specific cells of the sheep uterus. J Steroid Biochem Mol Biol 2001, 77:281-287.
• [45]Dudley MW, Sheeler CQ, Wang H, Khan S: Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action. Proc Natl Acad Sci U S A 2000, 97:3696-3701.
• [46]Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T, Golan DE: Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1999, 96:2788-2793.
• [47]Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR: Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 2000, 97:5930-5935.
• [48]Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, Jackson EK: Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 2000, 278:27-33.
• [49]Yoon BK, Oh WJ, Kessel B, Roh CR, Choi D, Lee JH, Kim DK: 17Beta-estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause 2001, 8:58-64.
• [50]Chiang CE, Chen SA, Chang MS, Lin CI, Luk HN: Genistein directly inhibits L-type calcium currents but potentiates cAMP-dependent chloride currents in cardiomyocytes. Biochem Biophys Res Commun 1996, 223:598-603.